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Purpose/Objective: Precise target definition is of paramount 
importance in particle therapy. Inflammatory and post 
surgical alterations may interfere with target contouring. 
Early response evaluation would be clinically useful but is 
still problematic. 18F-FDG may not be the optimal radiodrug 
due to its high uptake in the brain, hindering precise 
evaluation of skull base invasion, and in inflammatory (post-
RT or post surgical) lesions.11C-methionine (MET) PET-CT has 
been reported as an effective alternative in previous studies 
thanks to its low uptake in normal brain and its high uptake 
in salivary gland tumors; however its high uptake in normal 
salivary gland and in oral mucosa may be a limit. 
Materials and Methods: From April 2013 to October 2014, 68 
patients affected by head and neck tumors and treated at 
CNAO with carbon ion radiotherapy have been investigated 
with MET PET–CT. Histology was: adenoid cystic carcinoma 
(60 patients), sarcoma (6 patients) mucoepidermoid 
carcinoma and melanoma (one patient each). Pretreatment 
MET PET-CT, registered and fused with simulation CT, was 
employed as a visual aid in target contouring. MR images (T2 
weighted, T1 weighted and post contrast T1 weighted) were 
also used with the same aim. Volumes with methionine 
uptake comparable with that of parotid glands were included 
in the high dose CTV; asymmetric findings with uptake 
intermediate between parotid and brain were included in the 
low dose CTV. Pre treatment MET failed to show abnormal 
uptake in 17 patients. In patients with elevated initial uptake 
a post treatment MET was performed one month after 
completion of radiotherapy. Pre and post treatment PET is 
available in 24 patients. The ratio between MET uptake in the 
treated volume and uptake in the brain (T/B ratio) was 
calculated pre and post radiotherapy. Dimensional response 
as detectable at MR has been investigated every 3 months 
since the end of radiotherapy.  
Results: Seventeen patients have shown a decrease of more 
than 10% in MET uptake after treatment.The tumor to brain 
ratio has shown a mean reduction of 27%.  
Post radiotherapy changes had a minimal impact on MET 
uptake at one month. The mean follow-up was 8 months and 
the mean volumetric change at the last follow-up was 49%. 
Conclusions: MET PET-CT is a useful tool in contouring and 
early response assessment of head and neck tumors treated 
with carbon ion radiotherapy. Post RT changes do not mask 
tumor response. MET uptake decreases significantly even 
after one month. Longer follow up is needed to correlate 
early MET PET-CT response with long-term outcome.  
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Purpose/Objective: Treatment for resectable locally 
advanced head and neck cancers (LAHNC) is generally 
multimodal, involving surgery followed by radiotherapy (RT) 
± chemotherapy (CT) depending on high-risk features such as 
extracapsular extension (ECE) and R1 resection. The optimal 
duration of overall treatment time (OTT) has been the 
subject of much discussion. Accepted wisdom is that the OTT 
should not exceed 100 days measured from the day of surgery 
to the end of adjuvant therapy. We questioned whether this 
was still true in an era of intensified treatment or whether 
further survival or locoregional control benefits could be 
obtained by using a shorter OTT. 
Materials and Methods: This analysis includes 272 pts. (med. 
F/U 23.9 mo.) with LAHNC (106 oropharynx, 43 
larynx/hypopharynx, 75 oral cavity, 18 nasal/paranasal sinus, 
30 unknown primary/other) treated adjuvantly with RT +/- 
platinum based CT depending on pathological risk factors 
(Gregoire et al 2010). CT was given at a dose of 100mg/ m² 
q21 days or 30 mg/m² weekly. All pts. had IMRT, 2 Gy/ 
fraction to a total dose of 60-66 Gy. Of the 272 pts. 64 (24%) 
had ECE and 201 (74%) were R0 status. 
Pts. were followed at regular intervals with a clinical 
examination, flexible endoscopy and imaging. Toxicity was 
scored according to the RTOG acute radiation morbidity 
criteria and the RTOG/EORTC late radiation morbidity 
criteria.. 
The clinical impact of OTT was assessed using the Kaplan-
Meier and Multivariate Cox regression analysis (MVA). 
Recursive partitioning analysis (RPA) was performed to 
predict an optimal OTT with regard to clinical outcome. 
Results: 223 (82%) pts. had their treatment delivered in <100 
days; 49 (18%) had a duration of ≥ 100 days. Baseline 
characteristics were similar for both groups. MVA identified 
R1 status (HR 2.2) vs R0 status (p=0.36) but not OTT ≥100 
days as an adverse risk factor (ARF) for disease-fre survival 
(DFS). OTT ≥100 days (HR 4.1 vs 100 days; p=0.00007), R1 
status (HR 2.1 vs R0; p=0.04), and ECE (HR 2.3 vs no ECE; 
p=0.0342) were identified as ARFs for overall survival (OS). 
The RPA tree identified OTT <87 days as a high-performance 
group and OTT ≥87 days as the low-performance group for 
DFS. 95 pts. completed their treatment within 87 days and 
110 in ≥87 days. There was no difference in the baseline 
characterstics. 
MVA identified OTT of ≥87 days from surgery to end of RT (HR 
2.2 vs <87 days) and R1 status (HR 2.3 vs R0) as ARFs for DFS. 
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This analysis found the ARFs for OS to be ≥87 days from 
surgery to end of RT (HR 3.3; p=0.0025 vs <87 days) and ECE 
(HR 2.6 vs no ECE; p=0.0133). Adverse events did not differ 
between the groups. 
Conclusions: The present analysis has shown that OTT can be 
an important factor in DFS. OTT of 87 days is challenging and 
requires careful coordination of procedures and disciplines 
between surgery and adjuvant therapy, as well as minimizing 
treatment delays during RT. Our findings suggest that 
treatment completed within as short a timeframe as possible 
appears to be associated with longer DFS and that this should 
be a goal. Further studies are needed to confirm these 
findings.  
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Purpose/Objective: To develop a methodology for using FDG 
PET/CT in adaptive DPBN in locally advanced head and neck 
squamous cell carcinoma (HNSCC) patients. Issues related to 
noise in PET and robustness against geometric errors are 
addressed. 
Materials and Methods: Five patients with locally advanced 
HNSCC scheduled for chemo-radiotherapy were imaged with 
FDG-PET/CT at baseline and after 5, 10 and 15 fractions of 
RT (2 patients were re-imaged only twice). The GTVPET was 
segmented with a gradient-based method. A double median 
filter reduces the impact of noise in the conversion from PET 
uptake to prescribed dose. Filtered FDG uptake values were 
linearly converted into a voxel-by-voxel prescription from 70 
(median uptake) to 86 Gy (highest uptake). To be robust 
against geometrical uncertainties, a PTVPET was obtained by 
applying a dilation of 2.5 mm to the entire prescription. 
Seven iso-uptake thresholds led to 7 sub-levels compatible 
with the Tomotherapy HiArt® Treatment Planning System. 
Planning aimed to deliver a median dose of 56 Gy and 70 Gy 
in 35 fractions on the elective and therapeutic PTVs, 
respectively. Plan quality was assessed with quality-volume 
histogram (QVH) and quality factor (QF, objective: <5%). For 
organs at risk (OARs), DVH constraints were the following: 
Dmean < 26-30 Gy for parotid glands, D2 < 30 Gy for PRV spinal 
cord and brain stem. At each time point, plans were 
generated using a 1 cm collimator width with a total of 3 to 4 
plans for each patient. Deformable image registration was 
used for automatic propagation of volumes of interest and 
dose summation of the 3 or 4 treatment plans (MIM vista®) 
(see figure). Finally, to simulate a treatment that is adaptive 
to anatomical evolution seen at CT but blind to changes in 
the PET signal, the pre-treatment dose map was deformed 
and assessed with QVHs on each per-treatment CT scan after 




Results: GTVPET segmentations were performed successfully 
until week 2 of RT but failed in 2 patients at week 3. QVH 
analysis showed high conformity for all plans (mean VQ=0.95 
93%; mean VQ=1.05 3.9%; mean QF 2.2%) demonstrating 
feasibility of the treatment. Good OAR sparing was achieved 
while keeping high plan quality (see table). When comparing 
biologic/anatomic adaptation versus only anatomic 
adaptation, QFs were improved in all cases (range 0.8 – 3.7%) 
with a median value of 2.1% and 4.7% for the biological 
adaptive and anatomic only adaptive strategy, respectively. 
 
Conclusions: Our results show that adaptive FDG-PET-based 
escalated dose painting in patients with locally advanced 
